The peptide was more efficacious than both teduglutide and another GLP-2 analogue in development, glepaglutide [(226); Table 3], and has started recruiting for phase III clinical trials in SBS patients (231). The gene discussed is GCG; the disease is macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.